GLP-2T 30 mg

Tirzepatide is a synthetic peptide therapeutic engineered to mimic and enhance the activity of the body’s natural incretin hormones. It’s best known as the active molecule in the FDA-approved drugs Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management), developed by Eli Lilly & Company. 

Tirzepatide works through dual incretin receptor activation:

• GIP receptor agonism enhances insulin secretion and may improve fat metabolism and insulin sensitivity.
• GLP-1 receptor agonism boosts glucose-dependent insulin release, suppresses glucagon, delays gastric emptying, and increases satiety.
  Together, these actions help regulate blood sugar and reduce appetite, contributing to improved metabolic control and weight loss.